Page 140 - Binder2

• Growing payer resistance and declining trust in
long-term biologics

But more than that, the opportunity cost is staggering.
Every year spent operating in patchwork mode is a year
where platform solutions—designed for immune
cooperation from the ground up—are delayed from
reaching patients.

That’s not just inefficient. It’s preventable loss.

What the Platform Future Enables

• Therapies that last not 12 months, but 10 years
• Delivery systems that don’t require
immunosuppressants to function
• A new generation of biologics with low ADA rates
by design
• Treatment sequences that maintain immune
harmony across first- and second-line therapies
• A business model built on durability, not attrition

This is the model the industry never built—because the
incentives never demanded it.
But the science is ready. The signals are clear.
And the systems that survive the next era of biologics will
be those built not just to launch, but to last.

The patchwork is unraveling.
It’s time to build the platform.

138